Resumen
Hypomethylating agents (HMAs) are standard of care for higher-risk myelodysplastic syndromes (MDS). However, less than half of patients achieve objective responses and most eventually lose their response. Pracinostat is a pan-histone deacetylase inhibitor with demonstrated activity in advanced myeloid malignancies. This phase II study explored the benefit of adding pracinostat to HMAs in MDS patients who did not respond to single-agent HMA treatment. The goal was to estimate the clinical improvement rate [complete remission (CR), marrow CR, partial response (PR) and haematological improvement]. Group 1 included patients with primary/secondary HMA failures; Group 2 included those who did not achieve response but had stable disease (SD) after single-agent HMAs. Forty-five patients (39 Group 1, 6 Group 2) received a median of 3 cycles. Among all patients, 1 (2%) had CR, 7 (16%) had marrow CR and 18 (40%) had SD; disease progression occurred in 3 (7%). Median overall survival was 5·7/5·6 months for Group 1/2. Grade ≥3 adverse events occurred in 38 patients (84%) leading to treatment discontinuation in 12 (33%). Adding pracinostat to HMAs did not improve outcomes in patients previously treated with HMAs. Frequent dose modifications/early discontinuation resulted in suboptimal drug exposure. A reduced pracinostat dose may improve tolerability and efficacy.
| Idioma original | English |
|---|---|
| Páginas (desde-hasta) | 404-412 |
| Número de páginas | 9 |
| Publicación | British Journal of Haematology |
| Volumen | 188 |
| N.º | 3 |
| DOI | |
| Estado | Published - feb 1 2020 |
Nota bibliográfica
Publisher Copyright:© 2019 British Society for Haematology and John Wiley & Sons Ltd
Financiación
The authors would like to thank the patients who participated in this study and the staff at the study sites who cared for them. This study was sponsored and funded by MEI Pharma. Editorial support of formatting the paper for BJH was provided by Jennifer Vanden Burgt, an independent medical writer, and funded by Helsinn Healthcare.
| Financiadores |
|---|
| Helsinn Healthcare |
| Jennifer Vanden Burgt |
| MEI Pharma |
ASJC Scopus subject areas
- Hematology
Huella
Profundice en los temas de investigación de 'A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy'. En conjunto forman una huella única.Citar esto
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver